• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IRIDEX Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    3/13/26 4:16:13 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $IRIX alert in real time by email
    8-K
    0001006045false00010060452026-03-092026-03-09

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    March 9, 2026

     

    Date of Report (date of earliest event reported)

     

    IRIDEX CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware

    000-27598

    77-0210467

    (State or other jurisdiction of
    incorporation or organization)

    (Commission File Number)

    (I.R.S. Employer
    Identification Number)

    1212 Terra Bella Avenue
    Mountain View, California 94043

    (Address of principal executive offices, including zip code)

     

    (650) 940-4700

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    Securities registered pursuant to Section 12(b) of the Act:

    Title of Class

     

    Trading

    Symbol

     

    Name of Exchange on Which Registered

    Common Stock, par value $0.01 per share

     

    IRIX

     

    Nasdaq Capital Market

     

     


     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On March 9, 2026, IRIDEX Corporation (the “Company”) and SFIII Hellyer, LLC and SFIII FOS Hellyer Holding, LLC (the “Landlord”) entered into a triple net lease (the “Lease”) pursuant to which the Company will lease office space located at 5215 Hellyer Avenue in San Jose, California (the “Leased Space”) as the Company’s new corporate headquarters.

     

    The Leased Space consists of approximately 30,784 square feet. The Lease term is anticipated to commence on July 1, 2026 or such earlier date as the Company begins occupancy of the Leased Space for its business operations. The term of the Lease is 90 months from the commencement date. The Company has the right to extend the term of the Lease for an additional 60 months at the greater of (a) the Rent (as defined in the Lease) payable prior the commencement of the Option Term (as defined in the Lease) and (b) the then-prevailing Market Rent (as defined in the Lease). The Lease provides that minimum rent will abate during the six-month period following the commencement date. The annual minimum rent, to be paid in equal monthly installments, will be approximately $646,464 for the full initial lease year and increase to approximately $665,857 for the second full lease year. Thereafter, minimum rent will increase by approximately 3.0% per annum over the rest of the initial Lease term. The Company is also responsible for paying its share of operating expenses, taxes, and utilities. The Lease includes various covenants, indemnities, remedies, termination rights, sublease and transfer rights and other provisions customary for lease transactions of this nature.

     

    The foregoing summary of the Lease is only a summary of the material terms of the Lease, does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the full text of the Lease, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

     

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

     

    Item 9.01. Financial Statements and Exhibits.

    (d)

    Exhibits

     

    Exhibit No.

    Description

    10.1

    Lease dated March 9, 2026 by and between SFIII Hellyer, LLC and SFIII FOS Hellyer Holding, LLC and the Company.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    -2-


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934,as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

    IRIDEX CORPORATION

     

     

     

     

     

    By:

     

    /s/ Romeo R. Dizon

     

     

     

    Romeo R. Dizon

     

     

     

    Chief Financial Officer

     

     

     

     

    Date: March 13, 2026

     

     

     

     

    -3-


    Get the next $IRIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Iridex with a new price target

    Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $11.00 from $9.00 previously

    5/12/21 11:32:01 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital reiterated coverage on IRIDEX with a new price target

    Roth Capital reiterated coverage of IRIDEX with a rating of Buy and set a new price target of $9.00 from $6.00 previously

    3/9/21 8:09:06 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital reiterated coverage on Iridex with a new price target

    Roth Capital reiterated coverage of Iridex with a rating of Buy and set a new price target of $9.00 from $6.00 previously

    3/3/21 12:29:03 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dizon Romeo R bought $1,399 worth of shares (1,110 units at $1.26), increasing direct ownership by 0.93% to 121,000 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    3/9/26 1:05:37 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $2,942 worth of shares (2,200 units at $1.34), increasing direct ownership by 2% to 119,890 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/17/26 12:55:35 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $2,145 worth of shares (1,500 units at $1.43), increasing direct ownership by 1% to 117,690 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/12/26 10:05:32 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    SEC Filings

    View All

    IRIDEX Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IRIDEX CORP (0001006045) (Filer)

    3/13/26 4:16:13 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    IRIDEX Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IRIDEX CORP (0001006045) (Filer)

    1/12/26 9:11:03 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    IRIDEX Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - IRIDEX CORP (0001006045) (Filer)

    12/11/25 10:16:09 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

    MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and pro

    3/12/26 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex Announces Plans to Relocate Headquarters

    MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for a new lease (the "Lease"). The Company plans to move to the 31,000 square feet location and is expecting to generate savings of approximately $0.4 million in fiscal year 2026 and approximately $0.6 million in savings on an annualized b

    2/2/26 7:00:00 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

    MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Results Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%Achieved positive cash flow in the fourth quarterSold 15,800 Cyclo G6® probes compared to 13

    1/12/26 7:00:00 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Leadership Updates

    Live Leadership Updates

    View All

    Iridex Appoints Patrick Mercer as Chief Executive Officer

    MOUNTAIN VIEW, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the appointment of Patrick Mercer as the Company's Chief Executive Officer and President effective October 1, 2024. Previously Mr. Mercer served as the Company's Chief Operating Officer and President. David Bruce, the Company's prior Chief Executive Officer, is transitioning from the Company. Coincident to Mr. Mercer's appointment, Scott Shuda was appointed Executive Chairman of the Company's board of directors. M

    10/3/24 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust

    MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex' Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platform to advance clinical research. David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward mu

    1/24/24 8:00:00 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex Announces the Appointment of Beverly Huss to its Board of Directors

    MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective, March 17, 2022. In connection with Ms. Huss' appointment to the board, the size of the board was increased from five to six members as of the Effective Date. "I am very pleased to welcome Beverly to our board of directors," said Scott Shuda, chairman of the board of Iridex. "Beverly's extensive management and board experience in the medical device industry and proven track record with non-invasive a

    3/21/22 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Financials

    Live finance-specific insights

    View All

    Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

    MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the fourth quarter and full year 2025 and provide a business update after the close of trading on March 26, 2026. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and pro

    3/12/26 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex Reports Third Quarter 2025 Financial Results

    MOUNTAIN VIEW, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Financial Highlights Generated total revenue of $12.5 million, representing growth of 8% year-over-year compared to $11.6 million in the prior year quarterCyclo G6® product family revenue was $3.5 million, representing growth of 13% year-over-year compared to $3.1 million in the prior year quarter Sold 14,900 Cyclo G6 probes comp

    11/11/25 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025

    MOUNTAIN VIEW, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ:IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the third quarter 2025 and provide a business update after the close of trading on Tuesday, November 11, 2025. The Company's management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 from the US or +1-646-968-2525 internationally and providi

    10/28/25 4:05:00 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by IRIDEX Corporation

    SC 13D - IRIDEX CORP (0001006045) (Subject)

    11/23/22 4:57:01 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by IRIDEX Corporation

    SC 13D - IRIDEX CORP (0001006045) (Subject)

    9/20/22 2:06:59 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by IRIDEX Corporation (Amendment)

    SC 13G/A - IRIDEX CORP (0001006045) (Subject)

    2/10/22 8:17:17 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $IRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Dizon Romeo R bought $1,399 worth of shares (1,110 units at $1.26), increasing direct ownership by 0.93% to 121,000 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    3/9/26 1:05:37 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $2,942 worth of shares (2,200 units at $1.34), increasing direct ownership by 2% to 119,890 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/17/26 12:55:35 PM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Dizon Romeo R bought $2,145 worth of shares (1,500 units at $1.43), increasing direct ownership by 1% to 117,690 units (SEC Form 4)

    4 - IRIDEX CORP (0001006045) (Issuer)

    2/12/26 10:05:32 AM ET
    $IRIX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care